기본 정보
- CAS
22059-60-5- 표준 SMILES
CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C.O=P(O)(O)O- InChIKey
CGDDQFMPGMYYQP-UHFFFAOYSA-N- 분자식
- C21H32N3O5P
- 평균 분자량
- 437.5 g/mol
- 단동위원소 질량
- 437.20795813
개요
Disopyramide phosphate is an organoammonium phosphate. It is functionally related to a disopyramide.
이름 및 식별자
- 우선 이름
- Disopyramide Phosphate
- IUPAC
- 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide;phosphoric acid
- 영어명
- Disopyramid phosphate
- 분자식
- C21H32N3O5P
- 분자량
- 437.47
이름 및 동의어
DISOPYRAMIDE PHOSPHATE22059-60-5NorpaceRythmodanNorpace CrDirythmin saDiso-durilesSC-7031 PHOSPHATENSC-756744N6BOM1935WSC-13957CHEBI:4658
이름 더 보기
sc13957disopyramid phosphateDisopyramide phosphate CRSDISOPYRAMIDE PHOSPHATE SALTDisopyramid phosphate USP/EP/BPDisopyramide Phosphate (200 mg)
DTXSID309446852-(1-(Ammoniocarbonyl)-3-(diisopropylammonio)-1-phenylpropyl)pyridinium phosphate4-(diisopropylamino)-2-phenyl-2-(2-pyridyl)butanamide;phosphoric acidDirythminRythmodan retDirythmin-saIsomide crRefChem:56639
데이터베이스 식별자
- CAS
22059-60-5- PubChem CID
- 30928
- DTXSID
DTXSID30944685- ChEMBL
CHEMBL1201020- ChEBI
CHEBI:4658- UNII
- N6BOM1935W
- EC Number
- 244-756-1
물성
구조 계산 물성
- 극성 표면적
- 137 Ų
- 수소 결합 공여자 수
- 4
- 수소 결합 수용자 수
- 7
- 회전 가능 결합 수
- 8
- 무거운 원자 수
- 30
- 형식 전하
- 0
- 복잡도
- 459
실험 및 물리화학적 성질
Solubility>65.6 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Collision Cross Section179.9 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
물리화학적 성질
- 녹는점
- 202 · 202-204°C
- 저장 조건
- 2 · 2-8°C
- 용해도
- DMSO(약간 용해됨, 가열, 초음파 처리), 메탄올(약간 용해됨), 물(약간 용해됨)
- 물리적 상태
- solid
- 색상
- 흰색에서 황백색까지
- 주요 응용
- 의약품(소분자)
- InChI
- 1S/C21H29N3O.H3O4P/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19;1-5(2,3)4/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25);(H3,1,2,3,4)
- InChIKey
- CGDDQFMPGMYYQP-UHFFFAOYSA-N
- SMILES
- C(CCN(C(C)C)C(C)C)(C1=NC=CC=C1)(C1=CC=CC=C1)C(=O)N.P(=O)(O)(O)O
안전 및 규제
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
GHS 분류
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 41 reports by companies from 2 notifications to the ECHA C&L Inventory.
유해성 정보
Regulatory InformationDisopyramide phosphate: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 2-Pyridineacetamide, .alpha.-[2-[bis(1-methylethyl)amino]ethyl]-.alpha.-phenyl-, phosphate (1:1): Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)
독성 정보
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Disopyramide phosphate
vLess-DILI-concern
2
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
안전 데이터
- wgk
- 3
- rtecs
- UR8440000
- HS 번호
- 2933399090
- risk_code
- 22
- hazard_code
- Xn
- safety_code
- 36
- Hazard Classifications
- Acute Tox. 4 Oral
화학 및 산업
약리 정보
FDA Pharmacological Classification
DISOPYRAMIDE PHOSPHATE
Antiarrhythmic [EPC]
MeSH Pharmacological Classification
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.
응용 분야
용도Cardiac depressant (anti-arrhythmic).
일반 설명Disopyramide phosphate, -[2(diisopropylamino)ethyl]- -phenyl-2-pyridineacetamidephosphate (Norpace), is an oral and intravenousclass IA antiarrhythmic agent. It is quite similar to quinidineand procainamide in its electrophysiological properties, inthat it decreases phase 4 diastolic depolarization, decreasesconduction velocity, and has vagolytic properties.31 It is usedclinically in the treatment of refractory, life-threatening ventriculartachyarrhythmias. Oral administration of the drugproduces peak plasma levels within 2 hours. The drug isbound approximately 50% to plasma protein and has a halflifeof 6.7 hours in humans. More than 50% is excretedunchanged in the urine. Therefore, patients with renal insufficiencyshould be monitored carefully for evidence ofoverdose. Disopyramide phosphate commonly exhibits sideeffects of dry mouth, constipation, urinary retention, andother cholinergic blocking actions because of its structuralsimilarity to anticholinergic drugs.
상·하류 제품 정보
상류 원료
관련 반응
0건
현재 필터 조건에 해당하는 반응 기록이 없습니다.
화합물 노트
불러오는 중…